Fatrovax RHD


Rabbit haemorrhagic disease vaccine (inactivated, recombinant)

This medicine is authorised for use in the European Union.


Fatrovax RHD is a veterinary vaccine used to reduce mortality and signs of rabbit haemorrhagic disease (RHD). It contains two VLPs (virus-like particles) formed from proteins that are part of the ‘envelope’ of the viruses that cause the disease: one from rabbit haemorrhagic disease virus 1 (RHDV1) and one from rabbit haemorrhagic disease virus 2 (RHDV2).

This EPAR was last updated on 12/10/2021

Authorisation details

Product details
Fatrovax RHD
Agency product number
Active substance
  • Rabbit hemorrhagic disease virus 2 VP1AB
  • Rabbit hemorrhagic disease virus VP1A
International non-proprietary name (INN) or common name
Rabbit haemorrhagic disease vaccine (inactivated, recombinant)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Fatro S.p.A
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Via Emilia 285
40064 Ozzano Emilia

Product information

16/08/2021 Fatrovax RHD - EMEA/V/C/005301 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for leporidae

Therapeutic indication

For active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by RHDV1 and RHDV2.

Assessment history

How useful was this page?

Add your rating